NCT02535247 · OUTCOME

Recommended Phase II Dose of the Combination of Pembrolizumab and Copanlisib

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma · Source last updated 2022-07-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 6 months

Analysis population: Study did not progress to portion with combination of pembrolizumab and copanlisib

Groups in this outcome

Treatment

MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475

Combination

MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment	0
Combination	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

groups

description
MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
id
OG000
title
Treatment
description
MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
id
OG001
title
Combination

population Description

Study did not progress to portion with combination of pembrolizumab and copanlisib

reporting Status

POSTED

time Frame

6 months

title

Recommended Phase II Dose of the Combination of Pembrolizumab and Copanlisib

type

PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice